Skip to main content
OpenTrials

Clinical trial condition

Triple Negative Breast Neoplasms

Explore clinical trials studying Triple Negative Breast Neoplasms. Study availability and eligibility vary by location and protocol.

819 public trials 296 recruiting studies
Refine in advanced search Browse all conditions

Triple Negative Breast Neoplasms trial results

Completed

A Study of Efficacy and Safety of LAG525 in Combination With Spartalizumab, or With Spartalizumab and Carboplatin, or With Carboplatin, in Patients With Advanced Triple-negative Breast Cancer

NCT03499899

Conditions
Breast Diseases, Breast Neoplasms, Neoplasms, +5 more
Locations
  • Ironwood Cancer and Research Centers Chandler, Arizona, United States
  • Highlands Oncology Group Fayetteville, Arkansas, United States
  • Novartis Investigative Site Caba, Buenos Aires, Argentina
  • Novartis Investigative Site Wooloongabba, Queensland, Australia
View all 33 locations
View Trial Details
Completed

A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat

NCT02890069

Conditions
Adenocarcinoma, Breast Diseases, Breast Neoplasms, +36 more
Locations
  • UCLA Santa Monica Hematology / Oncology SC Santa Monica, California, United States
  • Sidney Kimmel Comprehensive Cancer Center Baltimore, Maryland, United States
  • Massachusetts General Hospital Boston, Massachusetts, United States
  • The Regents of the University of Michigan Ann Arbor, Michigan, United States
View all 25 locations
View Trial Details
Completed

Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer

NCT02657889

Conditions
Adnexal Diseases, Advanced Breast Cancer, Breast Cancer, +27 more
Locations
  • GSK Investigational Site Birmingham, Alabama, United States
  • GSK Investigational Site Phoenix, Arizona, United States
  • GSK Investigational Site Scottsdale, Arizona, United States
  • GSK Investigational Site Los Angeles, California, United States
View all 30 locations
View Trial Details
Completed

A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors

NCT03517488

Conditions
Adenocarcinoma, Adenoma, Adnexal Diseases, +129 more
Locations
  • Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute Los Angeles, California, United States
  • UCLA Hematology-Oncology Clinic (Westwood) Los Angeles, California, United States
  • University of California San Diego Moores Cancer Center San Diego, California, United States
  • University of California San Francisco Medical Center San Francisco, California, United States
View all 17 locations
View Trial Details
Completed

Study of CB-839 in Combination w/ Paclitaxel in Participants of African Ancestry and Non-African Ancestry With Advanced Triple Negative Breast Cancer (TNBC)

NCT03057600

Conditions
Breast Diseases, Breast Neoplasms, Neoplasms, +6 more
Locations
  • University of Alabama at Brimingham Birmingham, Alabama, United States
  • University of South Alabama, Mitchell Cancer Institute Mobile, Alabama, United States
  • Yale Cancer Center New Haven, Connecticut, United States
  • Georgetown University - Lombardi Comprehensive Cancer Center Washington D.C., District of Columbia, United States
View all 25 locations
View Trial Details
Completed

A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies

NCT03241173

Conditions
Adenocarcinoma, Adenoma, Adnexal Diseases, +74 more
Locations
  • The University of Alabama Birmingham (UAB) Birmingham, Alabama, United States
  • Scottsdale Healthcare Hospitals DBA HonorHealth Scottsdale, Arizona, United States
  • The Angeles Clinic and Research Institute Los Angeles, California, United States
  • Mount Sinai Medical Center of Florida, Inc. Miami, Florida, United States
View all 15 locations
View Trial Details

Related conditions